Oncotype DX In Pakistan

08/04/2023

It is your right to know more!

Genomics is the study of complex sets of genes and how they interact and function. In the case of breast cancer, a genomic test can help determine the likelihood that a given treatment will improve your outcome, enabling your physician and you to select the course of care that is right for you.
An example of these genomic tests is the Oncotype DX Breast Recurrence Score® test.

If you would like to receive more updates about breast cancer management and genomic testing, stay tuned to our next post and like our page.
For more information you can also get in touch with us and visit our www.nbpharma.com/oncotype

من حقكِ أن تعرفي أكثر!

علم الجينوم هو دراسة مجموعات معقدة من الجينات وكيفية تفاعلها ووظيفتها. في حالة سرطان الثدي، يمكن أن يساعد الاختبار الجينومي في تحديد احتمالية أن يحسن علاج ما من حالتكِ الصحية، مما يمكنكِ أنت وطبيبكِ من تحديد مسار الرعاية المناسب لك. يعد تحليل Oncotype DX Breast Recurrence Score® test واحدا من الأختبارات القائمة على تحليل الجينوم.

اذا رغبت في الحصول على آخر مستجدات علاج مرض سرطان الثدي والتحليل القائم على الجينومات، تابعي المنشورات اللاحقة واضغطي زر الإعجاب على صفحتنا على موقع فيسبوك.
للمزيد من المعلومات، يمكنك التواصل معنا وزيارة موقعنا الإلكتروني www.nbpharma.com/oncotype





Disclaimer: This page is promotional and managed by NewBridge Pharmaceuticals, its aim is to build a community about breast cancer awareness. NewBridge Pharmaceuticals does not offer medical advice, please refer to your physician for any health related inquiries.

15/11/2022

16/02/2022

14/09/2021

22/08/2021

19/08/2021

To learn more about OncotypeDX, visit : oncotypeiq.com

07/08/2021

In NCCN guidelines for the management of Node-positive Early-stage Breast Cancer, the Oncotype DX® Test

has been recognized as the “Preferred” and Only Multigene Test to Predict Chemotherapy Benefit.



Oncotype DX Breast Recurrence Score® test has been recognized as the only test that can be used for prediction of chemotherapy benefit in early-stage postmenopausal breast cancer patients with 1-3 positive axillary lymph nodes, including micrometastases, by the National Comprehensive Cancer Network (NCCN) in its updated guidelines for breast cancer.

The Oncotype DX® test is now the only test classified as “preferred” with the highest level of evidence for node-positive and postmenopausal node-positive patients.

Following are the treatment suggestions by 21 genes Oncotype Dx Premenopausal patients with (1-3 positive nodes)

Postmenopausal Patients with pT1-3, HR-positive, HER-2 Negative Tumors with recurrence score (RS)

27/05/2021

Not every Early stage Breast Cancer patient needs chemo.

14/04/2021

Happy Ramadan🌜

11/03/2021

Who can benefit from OncotypeDX?

For more details please visit:
www.oncotypeiq.com

For services details in Pakistan, feel free to contact us.😊🇵🇰
+92 301 8248006

03/03/2021

Why Oncotype Dx Test?

06/01/2021

Each cancer is as unique as the individual person affectecd by it.
Treatments can now be designed to the patients specific needs..NOT ALL PATIENTS WILL BENEFIT FROM CHEMOTHERAPY.

For more details feel free to contact us.🇵🇰

25/11/2020

A Monthly Breast Self Examination Reminder for all the ladies out there.